Your browser doesn't support javascript.
loading
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy.
Korb, Manisha; Peck, Allison; Alfano, Lindsay N; Berger, Kenneth I; James, Meredith K; Ghoshal, Nupur; Healzer, Elise; Henchcliffe, Claire; Khan, Shaida; Mammen, Pradeep P A; Patel, Sujata; Pfeffer, Gerald; Ralston, Stuart H; Roy, Bhaskar; Seeley, William W; Swenson, Andrea; Mozaffar, Tahseen; Weihl, Conrad; Kimonis, Virginia.
Afiliación
  • Korb M; Department of Neurology, University of California - Irvine School of Medicine, Orange, CA, USA. mkak@uci.edu.
  • Peck A; Cure VCP Disease, Americus, GA, USA.
  • Alfano LN; The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
  • Berger KI; Department of Medicine (Pulmonary), NYU Grossman School of Medicine, New York, NY, USA.
  • James MK; The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
  • Ghoshal N; Department of Neurology and Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.
  • Healzer E; Thriving Hope Consulting, Vinton, IA, USA.
  • Henchcliffe C; Department of Neurology, University of California - Irvine School of Medicine, Orange, CA, USA.
  • Khan S; Department of Neurology & Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Mammen PPA; Department of Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Patel S; Wellness with Sujata, Wadsworth, OH, USA.
  • Pfeffer G; Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
  • Ralston SH; Institute of Genetics and Cancer at the University of Edinburgh, Edinburgh, SCT, UK.
  • Roy B; Department of Neurology, Yale School of Medicine, New Haven, CT, USA.
  • Seeley WW; Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
  • Swenson A; Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
  • Mozaffar T; Department of Neurology, University of California - Irvine School of Medicine, Orange, CA, USA.
  • Weihl C; Department of Pathology & Laboratory Medicine, University of California - Irvine School of Medicine, Orange, CA, USA.
  • Kimonis V; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Orphanet J Rare Dis ; 17(1): 23, 2022 01 29.
Article en En | MEDLINE | ID: mdl-35093159
Valosin-containing protein (VCP) associated multisystem proteinopathy (MSP) is a rare inherited disorder that may result in multisystem involvement of varying phenotypes including inclusion body myopathy, Paget's disease of bone (PDB), frontotemporal dementia (FTD), parkinsonism, and amyotrophic lateral sclerosis (ALS), among others. An international multidisciplinary consortium of 40+ experts in neuromuscular disease, dementia, movement disorders, psychology, cardiology, pulmonology, physical therapy, occupational therapy, speech and language pathology, nutrition, genetics, integrative medicine, and endocrinology were convened by the patient advocacy organization, Cure VCP Disease, in December 2020 to develop a standard of care for this heterogeneous and under-diagnosed disease. To achieve this goal, working groups collaborated to generate expert consensus recommendations in 10 key areas: genetic diagnosis, myopathy, FTD, PDB, ALS, Charcot Marie Tooth disease (CMT), parkinsonism, cardiomyopathy, pulmonology, supportive therapies, nutrition and supplements, and mental health. In April 2021, facilitated discussion of each working group's conclusions with consensus building techniques enabled final agreement on the proposed standard of care for VCP patients. Timely referral to a specialty neuromuscular center is recommended to aid in efficient diagnosis of VCP MSP via single-gene testing in the case of a known familial VCP variant, or multi-gene panel sequencing in undifferentiated cases. Additionally, regular and ongoing multidisciplinary team follow up is essential for proactive screening and management of secondary complications. The goal of our consortium is to raise awareness of VCP MSP, expedite the time to accurate diagnosis, define gaps and inequities in patient care, initiate appropriate pharmacotherapies and supportive therapies for optimal management, and elevate the recommended best practices guidelines for multidisciplinary care internationally.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteítis Deformante / Miositis por Cuerpos de Inclusión / Esclerosis Amiotrófica Lateral Tipo de estudio: Guideline / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteítis Deformante / Miositis por Cuerpos de Inclusión / Esclerosis Amiotrófica Lateral Tipo de estudio: Guideline / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos